1,066 results match your criteria Cephalalgia : an international journal of headache[Journal]


Serum levels of allopregnanolone, progesterone and testosterone in menstrually-related and postmenopausal migraine: A cross-sectional study.

Cephalalgia 2020 Jun 26:333102420937742. Epub 2020 Jun 26.

Unit of Medical Toxicology, Headache Centre and Drug Abuse; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.

Background: Reduced blood or cerebrospinal fluid levels of allopregnanolone are involved in menstrual cycle-linked CNS disorders, such as catamenial epilepsy. This condition, like menstrually-related migraine, is characterized by severe, treatment-resistant attacks. We explored whether there were differences in allopregnanolone, progesterone and testosterone serum levels between women with menstrually-related migraine (MM, n = 30) or postmenopausal migraine without aura who had suffered from menstrually-related migraine during their fertile age (PM, n = 30) and non-headache control women in fertile age (FAC, n = 30) or post-menopause (PC, n = 30). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420937742DOI Listing

Migraine presenting as isolated facial pain: A prospective clinical analysis of 58 cases.

Cephalalgia 2020 Jun 17:333102420933277. Epub 2020 Jun 17.

Orofacial Pain Service, Department of Oral Surgery, King's College Hospital NHS Foundation Trust, London, UK.

Background: Sparse evidence has detailed the clinical phenotype of migraine presenting as isolated facial pain. This was a prospective audit, part of our multidisciplinary facial pain service evaluation, aiming to phenotype patients with migraine presenting as isolated facial pain who attended our service between 2013 and 2018.

Results: Fifty-eight patients were diagnosed with migraine with isolated facial pain (F = 46, 79. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420933277DOI Listing

Differences in pituitary adenylate cyclase-activating peptide and calcitonin gene-related peptide release in the trigeminovascular system.

Cephalalgia 2020 Jun 2:333102420929026. Epub 2020 Jun 2.

Department of Clinical Experimental Research, Glostrup Research Institute, Rigshospitalet Glostrup, Glostrup, Denmark.

Background: Several neurotransmitters are expressed in the neurons of the trigeminal ganglion. One such signalling molecule is the pituitary adenylate cyclase-activating peptide (PACAP). PACAP signalling has been suggested to have a possible role in the pathophysiology of primary headaches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420929026DOI Listing

Determination of psychosocial factors in cluster headache - construction and psychometric properties of the Cluster Headache Scales (CHS).

Cephalalgia 2020 Jun 2:333102420928076. Epub 2020 Jun 2.

Migraine and Headache Clinic Königstein, Königstein, Germany.

Background: Cluster headache (CH) is clinically associated with considerable psychosocial burden. However, instruments to assess and characterize psychosocial factors in cluster headache more specifically are lacking. This study aimed to develop a self-report questionnaire, which assesses the broadest possible spectrum of psychosocial factors in cluster headache, the Cluster Headache Scales (CHS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420928076DOI Listing

Dizziness and vertigo during the prodromal phase and headache phase of migraine: A systematic review and meta-analysis.

Cephalalgia 2020 Apr 29:333102420921855. Epub 2020 Apr 29.

BIDMC Comprehensive Headache Center, Department of Anesthesia, Critical Care and Pain Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Objective: To assess the proportion of individuals who report dizziness and/or vertigo during the prodromal phase or headache phase of migraine.

Methods: The databases of MEDLINE and EMBASE were searched for studies on dizziness and/or vertigo during the prodromal phase or headache phase of migraine. Pooled relative frequencies were estimated using a random-effects meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420921855DOI Listing

Identification of candidate proteomic markers in the serum of medication overuse headache patients: An exploratory study.

Cephalalgia 2020 Apr 29:333102420921847. Epub 2020 Apr 29.

Department of Surgery, Medicine, Dentistry and Morphological Science with Transplant Surgery, Oncology and Regenerative Medicine Relevance, Proteomic Lab, University of Modena and Reggio Emilia, Modena, Italy.

Purpose Of The Study: The pathophysiological mechanism of medication overuse headache is uncertain; no distinctive markers have been described right now. The aim of this study was to conduct proteomic analyses on serum samples from patients with medication overuse headache and healthy individuals. Specifically, mono- (SDS-PAGE) and two-dimensional gel electrophoresis (2-DE) followed by liquid chromatography tandem mass spectrometry (LC-MS/MS) were used to evaluate changes in serum proteins. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420921847DOI Listing

Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine.

Cephalalgia 2020 Apr 27:333102420920642. Epub 2020 Apr 27.

Eli Lilly and Company, Indianapolis, IN, USA.

Background: This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials.

Methods: Immunogenicity data were analyzed from baseline and double-blind, placebo-controlled phases of the 3-month chronic migraine study REGAIN, the 6-month episodic migraine studies EVOLVE-1 and EVOLVE-2, and from baseline and open-label phases of the 12-month chronic and episodic migraine Study CGAJ. The incidence of baseline antidrug antibodies, treatment-emergent antidrug antibodies, neutralizing antidrug antibodies, and the effect of antidrug antibody titer on pharmacokinetics and pharmacodynamics were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420920642DOI Listing

Cortical morphological changes in chronic migraine in a Taiwanese cohort: Surface- and voxel-based analyses.

Cephalalgia 2020 May 16;40(6):575-585. Epub 2020 Apr 16.

Department of Neurology, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.

Background: Previous voxel- or surface-based morphometric analysis studies have revealed alterations in cortical structure in patients with chronic migraine, yet with inconsistent results. The discrepancies may be derived partly from the sample heterogeneity. Employing both methods in a clinically homogenous group may provide a clearer view. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420920005DOI Listing

Effect of genetic liability to migraine on cognition and brain volume: A Mendelian randomization study.

Cephalalgia 2020 Apr 4:333102420916751. Epub 2020 Apr 4.

Division of Preventive Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Objective: To investigate potential causality between genetic liability to migraine and Alzheimer's disease, intelligence, and brain volume using two-sample Mendelian randomization.

Methods: The exposure consisted of independent genetic variants associated with migraine in the largest (59,674 cases/316,078 controls) published genome-wide association study. Outcomes included Alzheimer's disease (71,880 cases/383,378 controls), a measure of general intelligence (n = 269,867), intracranial volume (n = 11,373), and seven subcortical brain volumes (n ∼ 13,000), all with available genome-wide association study summary statistics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420916751DOI Listing

Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.

Cephalalgia 2020 Jun 29;40(7):639-649. Epub 2020 Mar 29.

University of Pennsylvania, Philadelphia, PA, USA.

Background: Triptans are the most commonly prescribed acute treatments for migraine; however, not all triptan users experience adequate response. Information on real-world resource use and costs associated with triptan insufficient response are limited.

Methods: A retrospective claims analysis using US commercial health plan data between 2012 and 2015 assessed healthcare resource use and costs in adults with a migraine diagnosis newly initiating triptans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420915167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273744PMC

Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: A human pharmacological triggering study.

Cephalalgia 2020 Mar 12:333102420910114. Epub 2020 Mar 12.

Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Background: Studying a spontaneous migraine attack is challenging, particularly the earliest components. Nitroglycerin is a potent, reliable and reproducible migraine trigger of the entirety of the migraine attack, making its use experimentally attractive.

Methods: Fifty-three subjects with migraine with a history of spontaneous premonitory symptoms were exposed to a 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420910114DOI Listing

Development of a measure to assess acceptance of headache: The Headache Acceptance Questionnaire (HAQ).

Cephalalgia 2020 Feb 18:333102420907596. Epub 2020 Feb 18.

Department of Psychology, University of Mississippi, Oxford, MS, USA.

Background: Disability resulting from headache disorders is attributable in part to avoidant coping. Acceptance of pain connotes a willingness to experience pain in the service of life values, such that meaningful activities and goals are pursued despite pain. Acceptance facilitates positive health outcomes but has rarely been investigated in headache. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420907596DOI Listing
February 2020

Have the IHS been followed? Laying the ground for the 4th edition.

Cephalalgia 2020 Feb 14:333102420906843. Epub 2020 Feb 14.

Headache Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.

Background: The International Headache Society (IHS) has published four editions of in the past 28 years. This continuous update process has been driven by the increasing amount of scientific data in the field of migraine and by the need to continuously improve the quality of trials.

Objectives: To illustrate: i) the results of the analysis on the adherence of published trials to the 3rd edition published in 2012, in order to identify the critical areas that needed to be addressed in the 4th edition and ii) the changes introduced in this latter edition for improving adherence and methodology robustness. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102420906843DOI Listing
February 2020

Familial trigeminal neuralgia - a systematic clinical study with a genomic screen of the neuronal electrogenisome.

Cephalalgia 2020 Jan 13:333102419897623. Epub 2020 Jan 13.

Department of Human Neuroscience, Sapienza University, Rome, Italy.

Objective: This cross-sectional study examined, for the first time, a large cohort of patients with trigeminal neuralgia, to ascertain the occurrence of familial cases, providing a systematic description of clinical features of familial disease. Since there is evidence linking hyperexcitability of trigeminal ganglion neurons to trigeminal neuralgia, we also carried out an exploratory genetic analysis of the neuronal electrogenisome in these patients.

Methods: We recorded familial occurrence by systematically interviewing all patients with a definite diagnosis of classical or idiopathic trigeminal neuralgia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419897623DOI Listing
January 2020

Focus group findings on the migraine patient experience during research studies and ideas for future investigations.

Cephalalgia 2020 Jun 23;40(7):712-734. Epub 2019 Dec 23.

Albert Einstein College of Medicine, Bronx, NY, USA.

Objectives: We conducted focus groups in people who had participated in mobile health (mHealth) studies of behavioral interventions for migraine to better understand: (a) Participant experience in the recruitment/enrollment process; (b) participant experience during the studies themselves; (c) ideas for improving participant experience for future studies.

Methods: We conducted four focus groups in people who had agreed to participate in one of three studies involving mHealth and behavioral therapy for migraine. Inclusion criteria were being age 18-80, owning a smartphone, and having four or more headache days per month. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419888230DOI Listing

Clinical features and sex differences in pediatric post-traumatic headache: A retrospective chart review at a Boston area concussion clinic.

Cephalalgia 2020 Jun 22;40(7):701-711. Epub 2019 Dec 22.

Boston Children's Hospital, Boston, MA, USA.

Background: Often concussion/mTBI triggers a chronic headache syndrome called persistent post-traumatic headache (P-PTH) that can last from months to years post-injury, and produce significant disruption of childhood education, social interaction and development. Although prevalent and highly disabling, P-PTH is underrepresented in headache and pain research and lacks clear definition and pathophysiology. Clinical presentation of P-PTH frequently resembles that of other headache disorders, like migraine, yet the pathophysiological mechanisms are distinct and not fully understood, making the disorder difficult to treat in the clinical setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419896754DOI Listing

Quantification of photophobia in visual snow syndrome: A case-control study.

Cephalalgia 2020 Apr 22;40(4):393-398. Epub 2019 Dec 22.

Department of Neurology, Ludwig Maximilians University Munich, University Hospital - Großhadern, Munich, Germany.

Objective: To quantify photophobia in visual snow syndrome (VSS), a debilitating migraine-associated visual disturbance manifesting with continuous "TV snow-like" flickering dots in the entire visual field and additional visual symptoms, such as photophobia.

Methods: Photophobia was compared between 19 patients with VSS and 19 controls matched for age, sex, migraine and aura using the Leiden Visual Sensitivity Scale (L-VISS).

Results: Patients with VSS had an increased L-VISS-score compared to matched controls [(22. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419896780DOI Listing

The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response.

Cephalalgia 2020 01 9;40(1):28-38. Epub 2019 Dec 9.

Amgen Inc., Thousand Oaks, CA, USA.

Objective: To assess the efficacy of erenumab across the spectrum of response thresholds (≥50%, ≥75%, 100%) based on monthly migraine days (MMD) reduction in patients with chronic migraine from a 12-week, randomized study (NCT02066415).

Methods: Patients (n = 667) received (3:2:2) placebo or erenumab 70/140 mg once-monthly. The proportion of patients achieving a given response threshold was assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419894559DOI Listing
January 2020

Annual indirect costs secondary to headache disability in Brazil.

Cephalalgia 2020 May 22;40(6):597-605. Epub 2019 Nov 22.

Hospital Israelita Albert Einstein, São Paulo, Brazil.

Background: Disability imposed by headache disorders constitutes an expressive economic burden, mostly from indirect costs due to absenteeism and presenteeism.

Objective: To estimate indirect costs from absenteeism and presenteeism due to headache disorders in Brazil.

Methods: In a secondary, descriptive analysis of two nationwide databases, we estimated indirect costs based on headache-related disability and socioeconomic data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419889357DOI Listing

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine.

Cephalalgia 2020 Apr 21;40(5):470-477. Epub 2019 Nov 21.

Teva Pharmaceutical Industries Ltd, Frazer, PA, USA.

Background: Fremanezumab, a fully humanized monoclonal antibody targeting calcitonin gene-related peptide, has demonstrated efficacy for the preventive treatment of migraine in adults.

Objective: To evaluate the effect of fremanezumab treatment on acute headache medication use and migraine-associated symptoms in patients with episodic migraine.

Methods: In the Phase 3 HALO trial, patients with episodic migraine were randomized to receive subcutaneous fremanezumab monthly (225 mg at baseline, weeks 4 and 8), fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8), or placebo over a 12-week period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419885905DOI Listing
April 2020
5 Reads

Hippocampal and trigeminal nerve volume predict outcome of surgical treatment for trigeminal neuralgia.

Cephalalgia 2020 May 21;40(6):586-596. Epub 2019 Nov 21.

Division of Neurosurgery, Department of Surgery, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

Background: Many medically-refractory trigeminal neuralgia patients are non-responders to surgical treatment. Few studies have explored how trigeminal nerve characteristics relate to surgical outcome, and none have investigated the relationship between subcortical brain structure and treatment outcomes.

Methods: We retrospectively studied trigeminal neuralgia patients undergoing surgical treatment with microvascular decompression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419877659DOI Listing

Epidemiology and determinants of chronic migraine: A real-world cohort study, with nested case-control analysis, in primary care in Italy.

Cephalalgia 2020 Apr 19;40(5):461-469. Epub 2019 Nov 19.

Health Search, Italian College of General Practitioners and Primary Care, Florence, Italy.

Background: The proper identification of chronic migraine is one of the mainstays for general practitioners. This study therefore aims to assess the epidemiology and determinants of chronic migraine in primary care in Italy by testing five operational case definition algorithms.

Methods: Five case definition algorithms defining chronic migraine were developed to estimate the prevalence and incidence rate of chronic migraine in the Health Search database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419889351DOI Listing

Long-term tolerability and nonvascular safety of erenumab, a novel calcitonin gene-related peptide receptor antagonist for prevention of migraine: A pooled analysis of four placebo-controlled trials with long-term extensions.

Cephalalgia 2019 Dec 10;39(14):1798-1808. Epub 2019 Nov 10.

Amgen Inc, Thousand Oaks, CA, USA.

Background: Efficacy and safety of erenumab have been evaluated in a comprehensive clinical development program resulting in approval for migraine prevention in over 40 countries to date.

Methods: This integrated safety analysis included four double-blind randomized trials and their extensions (up to three-plus years). Safety endpoints included exposure-adjusted patient incidences of adverse events, serious adverse events, and anti-erenumab antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419888222DOI Listing
December 2019

The relation between emotion regulation and migraine: A cross-cultural study on the moderating effect of culture.

Cephalalgia 2020 Apr 5;40(4):384-392. Epub 2019 Nov 5.

Migraine and Headache Clinic Königstein, Königstein im Taunus, Germany.

Background: Effects of emotion suppression on physical health might be contingent on culture. Existing research on emotion regulation has mainly included western participants. Herewith the question arises, whether this gained expertise is transferable to an Asian culture. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419885394DOI Listing

Structural connectivity alterations in chronic and episodic migraine: A diffusion magnetic resonance imaging connectomics study.

Cephalalgia 2020 Apr 1;40(4):367-383. Epub 2019 Nov 1.

Imaging Processing Laboratory, Universidad de Valladolid, Valladolid, Spain.

Objective: To identify possible structural connectivity alterations in patients with episodic and chronic migraine using magnetic resonance imaging data.

Methods: Fifty-four episodic migraine, 56 chronic migraine patients and 50 controls underwent T1-weighted and diffusion-weighted magnetic resonance imaging acquisitions. Number of streamlines (trajectories of estimated fiber-tracts), mean fractional anisotropy, axial diffusivity and radial diffusivity were the connectome measures. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419885392DOI Listing

Predictors of episodic migraine transformation to chronic migraine: A systematic review and meta-analysis of observational cohort studies.

Cephalalgia 2020 Apr 21;40(5):503-516. Epub 2019 Oct 21.

Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.

Background And Purpose: An estimated 2.5-3.1% of people with episodic migraine develop chronic migraine in a year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419883355DOI Listing
April 2020
1 Read

Brain state monitoring for the future prediction of migraine attacks.

Cephalalgia 2020 Mar 17;40(3):255-265. Epub 2019 Sep 17.

Research and Development Unit, Neuroverse, Inc., San Diego, CA, USA.

Background: Migraine attacks are unpredictable, precluding preemptive interventions and leading to lack of control over individuals' lives. Although there are neurophysiological changes 24-48 hours before migraine attacks, so far, they have not been used in patients' management. This study evaluates the applicability and the ability to identify pre-attack changes of daily "at home" electroencephalography obtained with a portable system for migraine patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419877660DOI Listing
March 2020
1 Read

Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial.

Cephalalgia 2019 Oct 15;39(12):1475-1487. Epub 2019 Sep 15.

Leiden University Medical Center, Leiden, The Netherlands.

Introduction: Non-invasive vagus nerve stimulation (nVNS; gammaCore®) has the potential to prevent migraine days in patients with migraine on the basis of mechanistic rationale and pilot clinical data.

Methods: This multicentre study included a 4-week run-in period, a 12-week double-blind period of randomised treatment with nVNS or sham, and a 24-week open-label period of nVNS. Patients were to administer two 120-second stimulations bilaterally to the neck three times daily (6-8 hours apart). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419876920DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6791025PMC
October 2019
1 Read

Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).

Cephalalgia 2019 Oct 21;39(11):1343-1357. Epub 2019 Aug 21.

California Medical Clinic for Headache, Santa Monica, CA, USA.

Objectives: To address the need for long-term lasmiditan data, the GLADIATOR study evaluated the safety (primary) and efficacy (secondary) of lasmiditan for the intermittent, acute treatment of migraine attacks for up to 1 year.

Methods: In this prospective, randomized, open-label, Phase 3 study, patients who had completed either of two single-attack studies were offered the opportunity to be randomized 1:1 to lasmiditan 100 mg or 200 mg. Patients were asked to use lasmiditan as the first treatment for each new migraine attack of at least moderate severity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419864132DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779019PMC
October 2019
3 Reads

Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis.

Cephalalgia 2019 Jul 10;39(8):967-977. Epub 2019 Jun 10.

2 NIHR-Wellcome Trust King's Clinical Research Facility, King's College London, UK.

Background: Two randomized, double-blind, sham-controlled trials (ACT1, ACT2) evaluated non-invasive vagus nerve stimulation (nVNS) as acute treatment for cluster headache. We analyzed pooled ACT1/ACT2 data to increase statistical power and gain insight into the differential efficacy of nVNS in episodic and chronic cluster headache.

Methods: Data extracted from ACT1 and ACT2 were pooled using a fixed-effects model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419856607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637721PMC
July 2019
14 Reads

Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: An observational cohort study.

Cephalalgia 2019 Oct 13;39(12):1544-1559. Epub 2019 Jun 13.

Optum Epidemiology, Boston, MA, US.

Introduction: This study quantified risks of cardiovascular, cerebrovascular, and mortality events among patients with migraine receiving prophylaxis.

Methods: Patients with migraine aged 18-65 years were identified from 2010 through 2015 within a United States administrative claims database. Topiramate initiators during follow-up were propensity score-matched separately to anticonvulsant, cardiovascular treatment, antidepressant, and other prophylactic treatment initiators. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419856630DOI Listing
October 2019
7 Reads

The persistence versus interchangeability of migraine and tension-type headaches in a 5-year population-based validated survey.

Cephalalgia 2020 01 4;40(1):39-48. Epub 2019 Jun 4.

Department of Neurology, Uludag School of Medicine, Uludag University, Bursa, Turkey.

Objective: The aim of this population-based validated study was to determine the course of tension-type headache and migraine and to evaluate the predictors of persistence.

Methods: We evaluated the course of headache in a large population from the first assessment in 2008 through a second assessment in 2013. Then we examined the factors associated with persistent migraine and persistent tension-type headache. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419852359DOI Listing
January 2020
8 Reads

Treatment patterns and characteristics of patients with migraine in Japan: A retrospective analysis of health insurance claims data.

Cephalalgia 2019 Oct 1;39(12):1518-1534. Epub 2019 Jun 1.

Global Safety, Amgen, Thousand Oaks, CA, USA.

Objective: To describe treatment patterns of migraine patients in the Japan Medical Data Center (JMDC) database.

Methods: Patients aged ≥18 years with ≥1 inpatient or ≥2 outpatient migraine diagnoses, ≥1 outpatient diagnosis and ≥1 migraine-specific acute treatment (triptan or ergotamine), or ≥2 migraine-specific acute treatments from 1 May 2011 to 30 April 2014 were identified. Patients were required to be enrolled in a health plan for ≥1 year before and after the index date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419851855DOI Listing
October 2019
2 Reads

Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine.

Cephalalgia 2019 Oct 30;39(11):1455-1464. Epub 2019 May 30.

Amgen Inc., Thousand Oaks, CA, USA.

Background: Previously published three-month placebo-controlled and one-year open-label clinical trial data have provided information on the efficacy and safety of erenumab.

Methods: Interim analysis was undertaken from an ongoing five-year open-label treatment phase after all patients completed three years in the open-label treatment phase or discontinued the study. Adult patients with episodic migraine enrolled in the open-label treatment phase initially received 70 mg erenumab monthly. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419854082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6779015PMC
October 2019
16 Reads

Validation of a photophobia symptom impact scale.

Cephalalgia 2019 10 22;39(11):1445-1454. Epub 2019 May 22.

University of Utah, Department of Neurology, Salt Lake City, UT, USA.

Background: Routine assessment of photophobia in the clinical setting may underestimate the presence and severity of this condition. We aimed to develop and validate a questionnaire to improve evaluation of the impact of photophobia on activities of daily living, and to determine the relationship of this questionnaire to psychophysical assessment of light sensitivity thresholds.

Methods: We developed the 17-item Utah Photophobia Symptom Impact Scale (UPSIS-17) and compared its psychometric properties to the 8-item Korean Photophobia Questionnaire (KUMC-8). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419845641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999072PMC
October 2019
22 Reads

Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data.

Cephalalgia 2019 Jul 21;39(8):945-956. Epub 2019 May 21.

5 University of Duisbury-Essen, Essen, Germany.

Background: The Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) trials demonstrated efficacy/tolerability of onabotulinumtoxinA for headache prevention in adults with chronic migraine. This post hoc analysis assessed time of onset of onabotulinumtoxinA after the first treatment in total and responder populations and consistency weekly through five treatment cycles.

Methods: In the 24-week, double-blind, placebo-controlled phase of PREEMPT, individuals were randomized 1:1 to onabotulinumtoxinA (155-195 U) or placebo every 12 weeks for two cycles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825382DOI Listing
July 2019
12 Reads

Comparing migraine with and without aura to healthy controls using RNA sequencing.

Cephalalgia 2019 Oct 19;39(11):1435-1444. Epub 2019 May 19.

Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Background: Migraine mechanisms are *These authors contributed equally to this work. only partly known. Some studies have previously described genes differentially expressed between blood from migraineurs and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419851812DOI Listing
October 2019
17 Reads

The clinical spectrum of reversible cerebral vasoconstriction syndrome: The Italian Project on Stroke at Young Age (IPSYS).

Cephalalgia 2019 Sep 6;39(10):1267-1276. Epub 2019 May 6.

1 Dipartimento di Scienze Cliniche e Sperimentali, Clinica Neurologica, Università degli Studi di Brescia, Brescia, Italy.

Introduction: To describe clinical, neuroimaging, and laboratory features of a large cohort of Italian patients with reversible cerebral vasoconstriction syndrome.

Methods: In the setting of the multicenter Italian Project on Stroke at Young Age (IPSYS), we retrospectively enrolled patients with a diagnosis of definite reversible cerebral vasoconstriction syndrome according to the International Classification of Headache Disorders (ICHD)-3 beta criteria (6.7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419849013DOI Listing
September 2019
29 Reads
4.891 Impact Factor

A web-based, branching logic questionnaire for the automated classification of migraine.

Cephalalgia 2019 Sep 1;39(10):1257-1266. Epub 2019 May 1.

Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.

Objective: To identify migraineurs and headache-free individuals with an online questionnaire and automated analysis algorithm.

Methods: We created a branching-logic, web-based questionnaire - the Penn Online Evaluation of Migraine - to obtain standardized headache history from a previously studied cohort. Responses were analyzed with an automated algorithm to assign subjects to one of several categories based on ICHD-3 (beta) criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419847749DOI Listing
September 2019
14 Reads

Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults.

Cephalalgia 2019 Jul 1;39(8):1058-1066. Epub 2019 May 1.

6 Department of Neurology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.

Introduction: Since the definition of chronic migraine as a new disease entity in 2004, numerous clinical trials have examined the efficacy of preventive treatments in chronic migraine. Our aim was to assess the adherence of these trials to the Guidelines of the International Headache Society published in 2008.

Methods: We searched PubMed for controlled clinical trials investigating preventive treatment for chronic migraine in adults designed after the release of the Guidelines and published until December 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419847751DOI Listing
July 2019
6 Reads

The diagnostic accuracy of headache measurement instruments: A systematic review and meta-analysis focusing on headaches associated with musculoskeletal symptoms.

Cephalalgia 2019 Sep 18;39(10):1313-1332. Epub 2019 Apr 18.

6 University Medical Center Utrecht, Utrecht University, Department of Oral-Maxillofacial Surgery and Special Dental Care, Utrecht, the Netherlands.

Aim: To systematically review the available literature on the diagnostic accuracy of questionnaires and measurement instruments for headaches associated with musculoskeletal symptoms.

Design: Articles were eligible for inclusion when the diagnostic accuracy (sensitivity/specificity) was established for measurement instruments for headaches associated with musculoskeletal symptoms in an adult population. The databases searched were PubMed (1966-2018), Cochrane (1898-2018) and Cinahl (1988-2018). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419840777DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6710620PMC
September 2019
10 Reads

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.

Cephalalgia 2019 06 13;39(7):817-826. Epub 2019 Apr 13.

7 Amgen Inc., Thousand Oaks, CA, USA.

Background: Erenumab was effective and well tolerated in a pivotal clinical trial of episodic migraine that included subjects both naïve to, and those who had failed, previous preventives. Here we evaluated the efficacy and safety of erenumab (70 mg or 140 mg) versus placebo in the subgroup of patients who had previously failed preventive treatment(s): ≥1 or ≥2 prior failed migraine preventive categories, and in patients who had never failed.

Methods: Prespecified subgroup analyses evaluated change from baseline to months 4-6 (the primary endpoint of the blinded study phase) in monthly migraine days, achievement of ≥50% and ≥75% reduction in monthly migraine days, and change from baseline in acute migraine-specific medication days. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419835459DOI Listing
June 2019
31 Reads

Cyclic vomiting syndrome and benign paroxysmal torticollis are associated with a high risk of developing primary headache: A longitudinal study.

Cephalalgia 2019 Sep 13;39(10):1236-1240. Epub 2019 Apr 13.

1 Headache Center, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.

Background And Aim: Episodic syndromes that may be associated with migraine are a group of disorders affecting patients with migraine or with an increased risk of presenting it, and likely represent an early life expression of migraine. Cyclic vomiting syndrome and benign paroxysmal torticollis are well characterized and represent a frequent cause of request for specialist consultations. The aim of this study is to longitudinally assess the rate of headache in patients presenting with cyclic vomiting syndrome and benign paroxysmal torticollis during infancy, and to define the main clinical features of the disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419844542DOI Listing
September 2019
28 Reads

Differences in fibertract profiles between patients with migraine and those with persistent post-traumatic headache.

Cephalalgia 2019 Aug 26;39(9):1121-1133. Epub 2019 Mar 26.

1 Mayo Clinic Department of Neurology, Mayo Clinic, Phoenix, AZ, USA.

Objectives: Often, persistent post-traumatic headache and migraine are phenotypically similar. However, the similarities and differences in the neuropathological underpinnings of persistent post-traumatic headache and migraine require further understanding. We used diffusion tensor imaging (DTI) and a novel method for detecting subtle changes in fibertract integrity by measuring node-by-node parameters along each tract to compare fibertract profiles between those with migraine and those with persistent post-traumatic headache, and compared both cohorts to a group of controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418815650DOI Listing
August 2019
5 Reads

The spectrum of cluster headache: A case report of 4600 attacks.

Cephalalgia 2019 Aug 26;39(9):1134-1142. Epub 2019 Mar 26.

1 Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Glostrup, Denmark.

Introduction: Knowledge of the clinical features of cluster headache is mainly based on retrospective and cross-sectional studies. Here, we present a case of a chronic cluster headache patient who prospectively recorded timing and clinical features of all attacks for 6 years, aiming to describe the clinical spectrum and timing of cluster headache symptoms experienced and to identify daily and/or seasonal rhythmicity.

Methods: Registration of attack timing, duration, associated symptoms and severity was done prospectively on a smartphone application. Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/0333102419833081
Publisher Site
http://dx.doi.org/10.1177/0333102419833081DOI Listing
August 2019
10 Reads

Migraine classification using somatosensory evoked potentials.

Cephalalgia 2019 Aug 26;39(9):1143-1155. Epub 2019 Mar 26.

1 School of Electrical and Computer Engineering, Cornell University, Ithaca, NY, USA.

Objective: The automatic detection of migraine states using electrophysiological recordings may play a key role in migraine diagnosis and early treatment. Migraineurs are characterized by a deficit of habituation in cortical information processing, causing abnormal changes of somatosensory evoked potentials. Here, we propose a machine learning approach to utilize somatosensory evoked potential-based biomarkers for migraine classification in a noninvasive setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839975DOI Listing
August 2019
2 Reads

Deep brain stimulation of chronic cluster headaches: Posterior hypothalamus, ventral tegmentum and beyond.

Cephalalgia 2019 Aug 21;39(9):1111-1120. Epub 2019 Mar 21.

3 Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

Objective: We present long-term follow-up results and analysis of stimulation sites of a prospective cohort study of six patients with chronic cluster headaches undergoing deep brain stimulation of the ipsilateral posterior hypothalamic region.

Methods: The primary endpoint was the postoperative change in the composite headache severity score "headache load" after 12 months of chronic stimulation. Secondary endpoints were the changes in headache attack frequency, headache attack duration and headache intensity, quality of life measures at 12, 24, and 48 months following surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419839992DOI Listing
August 2019
7 Reads

Does insomnia modify the association between C-reactive protein and migraine? The Tromsø Study 2015-2016.

Cephalalgia 2019 Jul 12;39(8):1022-1029. Epub 2019 Mar 12.

1 Department of Neuroscience and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.

Background: The relationship between high sensitivity C-reactive protein and migraine is unclear. The aim of this cross-sectional population-based study was to investigate the association between high sensitivity C-reactive protein and types of headache, and to evaluate the impact of insomnia on this association.

Methods: A total of 20,486 (63%) out of 32,591 invited, aged ≥40 years or older, participated in the seventh wave of the Tromsø study conducted in 2015-2016 and had valid information on headache, insomnia and high sensitivity C-reactive protein. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418825370DOI Listing
July 2019
2 Reads

Functional connectivity of hypothalamus in chronic migraine with medication overuse.

Cephalalgia 2019 06 5;39(7):892-899. Epub 2019 Mar 5.

1 Department of Neurology, University Hospital of Toulouse, Toulouse, France.

Objective: To investigate the functional connectivity of the hypothalamus in chronic migraine compared to interictal episodic migraine in order to improve our understanding of migraine chronification.

Methods: Using task-free fMRI and ROI-to-ROI analysis, we compared anterior hypothalamus intrinsic connectivity with the spinal trigeminal nucleus in patients with chronic migraine (n = 25) to age- and sex-matched patients with episodic migraine in the interictal phase (n = 22). We also conducted a seed-to-voxel analysis with anterior hypothalamus as a seed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102419833087DOI Listing
June 2019
5 Reads

Leptin, adiponectin, and resistin blood adipokine levels in migraineurs: Systematic reviews and meta-analyses.

Cephalalgia 2019 Jul 24;39(8):1010-1021. Epub 2019 Feb 24.

1 Department of Clinical Biochemistry, Faculty of Allied Medical Sciences, Ilam University of Medical Sciences, Ilam, Iran.

Introduction: Migraine comorbidity with obesity is not new and studies have focused on how adipose tissue-derived substances such as adipokines might be involved in the migraine pathophysiology. Quantification of the nature and magnitude of the association between each adipokine including leptin, adiponectin and resistin with migraine pathophysiology is the objective of the current study.

Methods: Using systematic reviews and meta-analyses and standardized mean difference as effect size, the levels of three adipokines, leptin, adiponectin and resistin, have been investigated in migraineur subjects in the case-control studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418807182DOI Listing
July 2019
1 Read
4.891 Impact Factor